Trial Profile
An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects With Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Feb 2021
Price :
$35
*
At a glance
- Drugs Clarithromycin/clofazimine/rifabutin (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms MAPUS2
- Sponsors RedHill Biopharma
- 26 Feb 2020 This trial has been discontinued in Slovakia,according to European Clinical Trials Database record.
- 11 Oct 2019 According to a RedHill Biopharma media release, a total of 54 subjects entered the open-label extension study and 30 subjects completed 52 weeks of treatment.
- 11 Oct 2019 Interim Results presented in a RedHill Biopharma Media Release.